Vorasidenib
The question
To ask the Secretary of State for Health and Social Care, when he expects the drug Vorsidenib (Voranigo) to be made available to treat adults and children aged 12 years and over with grade 2 astrocytoma or oligodendroglioma carrying a susceptible IDH1 or IDH2 mutation.
Answered by Dr Zubir Ahmed
The National Institute for Health and Care Excellence (NICE) is the independent body that makes evidence-based recommendations on whether new medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. NICE is currently evaluating vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years old and over.
NICE published its draft guidance for consultation on 15 October and was unable to recommend it as a clinically and cost-effective use of NHS resources. The appraisal is still ongoing, and NICE will take the comments received fully into account in developing its final recommendations. The committee reviewed the consultation comments at the committee meeting on 20 November 2025. NICE currently expect to publish final guidance in January 2026.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →